Pharmacological chaperones for treating obesity
US9937165B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 6, 2016 |
| Grant date | Apr 10, 2018 |
| Priority date | — |
| Expiry date | May 6, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/723
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.